" /> CDK2/4/6 Inhibitor RGT-419B - CISMeF





Preferred Label : CDK2/4/6 Inhibitor RGT-419B;

NCIt synonyms : Cyclin-dependent Kinase 2/4/6 Inhibitor RGT-419B;

NCIt definition : An orally bioavailable third-generation inhibitor of cyclin-dependent kinase (CDK) types 2 (CDK2), 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK2/4/6 inhibitor RGT-419B selectively targets and inhibits CDK2, CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase and prevents CDK-mediated G1-S-phase transition. This leads to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are upregulated in many tumor cell types. In addition, RGT-419B may inhibit other kinases.;

Molecule name : RGT 419B; RGT-419B;

NCI Metathesaurus CUI : CL1794047;

Détails


Vous pouvez consulter :


Nous contacter.
29/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.